CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1664171
This article is part of the Research TopicChimeric Antigen Receptor T Cell Therapies and Bispecific Antibodies in Hematologic MalignanciesView all articles
Safety and Efficacy Assessment of Teclistamab in Relapsed/Refractory Amyloidosis: A Case Study
Provisionally accepted
- Shaoxing People's Hospital, Shaoxing, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Systemic light chain amyloidosis (AL) is an uncommon disorder of clonal plasma cells, marked by the creation of amyloid-forming immunoglobulin light chains that result in amyloid fibril formation and deposition, causing dysfunction in multiple organs. There is no established treatment protocol for patients with relapsed or refractory AL. Teclistamab is a bispecific antibody targeting B-cell maturation antigen (BCMA) and is approved for treating relapsed or refractory multiple myeloma (MM). The objective of our study was to report real-world data on the safety and efficacy of teclistamab in patients with relapsed/refractory AL.
Keywords: Amyloidosis, Teclistamab, Relapsed/refractory, bispecific antibody, Safety and efficacy
Received: 11 Jul 2025; Accepted: 02 Sep 2025.
Copyright: © 2025 CHEN, Zhang, YU, Fu, Fu and Feng. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Weiying Feng, Shaoxing People's Hospital, Shaoxing, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.